Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Milestone Pharmaceuticals Inc is a biotechnology business based in the US. Milestone Pharmaceuticals shares (MIST) are listed on the NASDAQ and all prices are listed in US Dollars. Milestone Pharmaceuticals employs 28 staff and has a market cap (total outstanding shares value) of USD$220.7 million.
|Latest market close||USD$7.17|
|52-week range||USD$1.71 - USD$23.245|
|50-day moving average||USD$6.412|
|200-day moving average||USD$6.3537|
|Wall St. target price||USD$13.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-10.837|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||1.70%|
|1 month (2020-12-18)||4.52%|
|3 months (2020-10-16)||0.42%|
|6 months (2020-07-17)||101.97%|
|1 year (2020-01-17)||-61.18%|
|2 years (2019-01-15)||N/A|
|3 years (2018-01-15)||N/A|
|5 years (2016-01-15)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-30.34%|
|Return on equity TTM||-50.71%|
|Market capitalisation||USD$220.7 million|
TTM: trailing 12 months
There are currently 348,528 Milestone Pharmaceuticals shares held short by investors – that's known as Milestone Pharmaceuticals's "short interest". This figure is 13.9% down from 404,950 last month.
There are a few different ways that this level of interest in shorting Milestone Pharmaceuticals shares can be evaluated.
Milestone Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Milestone Pharmaceuticals shares currently shorted divided by the average quantity of Milestone Pharmaceuticals shares traded daily (recently around 195802.24719101). Milestone Pharmaceuticals's SIR currently stands at 1.78. In other words for every 100,000 Milestone Pharmaceuticals shares traded daily on the market, roughly 1780 shares are currently held short.
However Milestone Pharmaceuticals's short interest can also be evaluated against the total number of Milestone Pharmaceuticals shares, or, against the total number of tradable Milestone Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Milestone Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Milestone Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0168% of the tradable shares (for every 100,000 tradable Milestone Pharmaceuticals shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Milestone Pharmaceuticals.
Find out more about how you can short Milestone Pharmaceuticals stock.
We're not expecting Milestone Pharmaceuticals to pay a dividend over the next 12 months.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.